Instinct Bio Completes Business Combination with Relativity Acquisition Corp. and Begins Nasdaq Trading as BIOT

The9 Limited’s Investee Nanyang Biologics Advances Planned Nasdaq Listing in US$1.5 Billion Business Combination

August 11, 2026

AI & Machine Learning

The9 Limited said its Singapore investee Nanyang Biologics Pte. Ltd. (NYB) received notice of effectiveness from the U.S. SEC for its Form F-4 registration statement tied to a previously announced business combination valued at about US$1.5 billion. The listing is planned on Nasdaq (ticker symbol “NYB”), subject to NYB’s SPAC extraordinary general meeting and Nasdaq approval.

Repligen Acquires BioLife Solutions for $1.5 Billion

July 23, 2026

Healthcare Services

Repligen has entered into a definitive agreement to acquire BioLife Solutions in a cash-and-stock transaction with an enterprise value of approximately $1.5 billion. The deal is expected to close in the fourth quarter of 2026, subject to BioLife shareholder approval and regulatory clearances.

INVO Bioscience Acquires NAYA Biosciences in All-Stock Merger

October 14, 2024

Healthcare Services

INVO Bioscience and NAYA Biosciences entered into a definitive all-stock merger agreement under which INVO would acquire 100% of NAYA in a reverse triangular merger. The combined company operates as NAYA Biosciences and trades on NASDAQ under the “NAYA” ticker after closing.

Ignyte Acquisition Corp. Completes Business Combination with Peak Bio Co., Ltd.

November 2, 2022

Biotechnology

Ignyte Acquisition Corp. completed its business combination with clinical-stage biopharmaceutical company Peak Bio Co., Ltd. The combined company began trading on NASDAQ as “Peak Bio, Inc.” under ticker “PKBO.” The transaction followed stockholder approvals at Ignyte’s special meeting on October 25, 2022.

Haymaker Acquisition Corp. III Merges with Biote

June 3, 2022

Healthcare Services

Haymaker Acquisition Corp. III, a publicly traded SPAC, completed its merger with consumer-directed hormone optimization company Biote (transaction announced Dec 13, 2021; closed May 27, 2022). Biote operates a platform that trains and certifies practitioners and provides practice management software, marketing support and branded nutraceutical products, and had grown a network of roughly 4,700 Biote-certified practitioners in the U.S.

Equillium Acquires Bioniz Therapeutics

February 16, 2022

Biotechnology

Equillium, Inc. (Nasdaq: EQ) acquired privately held Bioniz Therapeutics, obtaining exclusive worldwide rights to Bioniz's pipeline (BNZ-1, BNZ-2, BNZ-3) and proprietary discovery platform in an all-stock transaction (5,699,492 shares, ~19.3% of Equillium outstanding) plus up to $57.5M in development milestones and up to $250M in sales milestones. The acquisition expands Equillium's immunology capabilities and pipeline, adding complementary clinical-stage cytokine-targeting assets and key research and clinical personnel.